Anti-Obesity Drugs Market Set to Register a CAGR of 16.10% and Reach USD 7.97 Billion by 2031 – Growth Plus Reports
April 10, 2023 09:00 ET
|
Growth Plus Reports
Newark, New Castle, USA, April 10, 2023 (GLOBE NEWSWIRE) -- According to a recent Growth Plus Reports assessment, the anti-obesity drugs market is estimated to reach US$ 7.97 billion by 2031, with a...
Ellen AB har erhållit en första uppfyllnadsorder för implementering av de probiotiska tampongerna i de fysiska butikerna på Norges största apotekskedja, Apotek 1
February 23, 2021 10:13 ET
|
Ellen AB
Ellen AB har tidigare kommunicerat att de utvidgar sin distribution och affär i Norge via Apotek 1, Norges största apotekskedja. Nu har den första uppfyllnadsordern kommit för återlansering och...
Bone and Joint Health Supplements market worldwide is projected to grow by US$5.3 Billion
May 22, 2020 22:13 ET
|
ReportLinker
New York, May 22, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Bone and Joint Health Supplements Industry" -...
Outlook on the World Market for Anti-Obesity Drugs 2019-2024
June 21, 2019 05:15 ET
|
Research and Markets
Dublin, June 21, 2019 (GLOBE NEWSWIRE) -- The "Anti-Obesity Drugs: Global Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering. This...
Navamedic ASA: Tom Rönnlund to step down as CEO
October 01, 2018 02:31 ET
|
Navamedic
Oslo, Oct 1, 2018 - Navamedic ASA (OSE: NAVA) today announces that Tom Rönnlund has tendered his resignation as CEO of Navamedic ASA and will leave the company at the end of 2018 to take up a position...
Navamedic ASA: Resultater for Q2 2018
August 24, 2018 01:58 ET
|
Navamedic
Oslo, 24. august 2018 - Navamedic ASA (OSE: NAVA) rapporterte driftsinntekter på NOK 45,2 millioner i andre kvartal 2018, ned fra NOK 89,7 millioner i samme periode i 2017, etter det planlagte...
Navamedic ASA: Q2 2018 results
August 24, 2018 01:58 ET
|
Navamedic
Oslo, August 24, 2018 - Navamedic ASA (OSE: NAVA) reported revenues of NOK 45.2 million in the second quarter of 2018, down from NOK 89.7 million in the same period in 2017, following the...
Navamedic ASA: Resultater for Q2 2018
August 24, 2018 01:25 ET
|
Navamedic
Oslo, 24. august 2018 - Navamedic ASA (OSE: NAVA) rapporterte driftsinntekter på NOK 45,2 millioner i andre kvartal 2018, ned fra NOK 89,7 millioner i samme periode i 2017, etter det planlagte utløpet...
Navamedic ASA: Q2 2018 results
August 24, 2018 01:25 ET
|
Navamedic
Oslo, August 24, 2018 - Navamedic ASA (OSE: NAVA) reported revenues of NOK 45.2 million in the second quarter of 2018, down from NOK 89.7 million in the same period in 2017, following the planned...
Navamedic ASA: Renews multiple key distribution agreements
August 21, 2018 02:01 ET
|
Navamedic
Oslo, August 21, 2018 - Navamedic ASA (OSE: NAVA) today announced it has renewed three partnership agreements with Vitaflo International Limited, Allerderm Laboratories and Qiagen GmbH for...